Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 7 (July)

1. Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients.
   Int J Clin Oncol, 10(3): 182-6. [Abstract] [Full-text]
2. Out-of-field photon and neutron dose equivalents from step-and-shoot intensity-modulated radiation therapy.
   Int J Radiat Oncol Biol Phys, 62(4): 1204-16. [Abstract] [Full-text]
3. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.
   Int J Radiat Oncol Biol Phys, 62(4): 981-7. [Abstract] [Full-text]
4. Sequential evaluation of prostate edema after permanent seed prostate brachytherapy using CT-MRI fusion.
   Int J Radiat Oncol Biol Phys, 62(4): 974-80. [Abstract] [Full-text]
5. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy.
   Int J Radiat Oncol Biol Phys, 62(4): 965-73. [Abstract] [Full-text]
6. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05.
   Int J Radiat Oncol Biol Phys, 62(4): 956-64. [Abstract] [Full-text]
7. Assessment of residual error for online cone-beam CT-guided treatment of prostate cancer patients.
   Int J Radiat Oncol Biol Phys, 62(4): 1239-46. [Abstract] [Full-text]
8. Comparative treatment planning on localized prostate carcinoma conformal photon- versus proton-based radiotherapy.
   Strahlenther Onkol, 181(7): 448-55. [Abstract] [Full-text]
9. Results of three dimensional conformal radiotherapy and hormonal therapy for local recurrence after radical prostatectomy.
   Strahlenther Onkol, 181(7): 442-7. [Abstract] [Full-text]
10. IMRT to escalate the dose to the prostate while treating the pelvic nodes.
    Strahlenther Onkol, 181(7): 431-41. [Abstract] [Full-text]
11. Interobserver delineation variation using CT versus combined CT + MRI in intensity-modulated radiotherapy for prostate cancer.
    Strahlenther Onkol, 181(7): 424-30. [Abstract] [Full-text]
12. Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells.
    Cancer Res, 65(13): 5769-77. [Abstract] [Full-text]
13. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread.
    Cancer Res, 65(13): 5761-8. [Abstract] [Full-text]
14. Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells.
    Cancer Res, 65(13): 5750-60. [Abstract] [Full-text]
15. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.
    Cancer Res, 65(13): 5730-9. [Abstract] [Full-text]
16. Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein.
    Cancer Res, 65(13): 5662-7. [Abstract] [Full-text]
17. High activity of mitochondrial glycerophosphate dehydrogenase and glycerophosphate-dependent ROS production in prostate cancer cell lines.
    Biochem Biophys Res Commun, 333(4): 1139-45. [Abstract] [Full-text]
18. Improved detection of prostate cancer using classification and regression tree analysis.
    J Clin Oncol, 23(19): 4322-9. [Abstract] [Full-text]
19. Proliferative lesions of prostate: a multivariate approach to differential diagnosis.
    Pathol Oncol Res, 11(2): 103-7. [Abstract] [Full-text]
20. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence.
    J Natl Cancer Inst, 97(13): 975-80. [Abstract] [Full-text]
21. Employment outcomes of men treated for prostate cancer.
    J Natl Cancer Inst, 97(13): 958-65. [Abstract] [Full-text]
22. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
    JAMA, 294(1): 66-70. [Abstract] [Full-text]
23. New directions for critical internet health studies: representing cancer experience on the web.
    Sociol Health Illn, 27(4): 515-40. [Abstract] [Full-text]
24. Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?
    Cancer, 104(2): 299-304. [Abstract] [Full-text]
25. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy.
    Cancer, 104(2): 290-8. [Abstract] [Full-text]
26. Radical prostatectomy: men's experiences and postoperative needs.
    J Clin Nurs, 14(7): 883-90. [Abstract] [Full-text]
27. Finding more meaning: the antecedents of uncertainty revisited.
    J Clin Nurs, 14(7): 863-8. [Abstract] [Full-text]
28. A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics.
    Am J Hum Genet, 77(2): 219-29. [Abstract] [Full-text]
29. A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model.
    Oncogene, 24(29): 4736-40. [Abstract] [Full-text]
30. Differential effects of gonadotropin-releasing hormone (GnRH)-I and GnRH-II on prostate cancer cell signaling and death.
    J Clin Endocrinol Metab, 90(7): 4287-98. [Abstract] [Full-text]
31. Protein C inhibitor (plasminogen activator inhibitor-3) expression in the CWR22 prostate cancer xenograft.
    Exp Mol Pathol, 79(1): 23-32. [Abstract] [Full-text]
32. The validity of the family relationships index as a screening tool for psychological risk in families of cancer patients.
    Psychooncology, 14(7): 546-54. [Abstract] [Full-text]
33. Inhibitors of tyrosine kinase inhibit the production of urokinase plasminogen activator in human prostatic cancer cells.
    APMIS, 113(5): 332-9. [Abstract] [Full-text]
34. Androgen deprivation therapy for prostate cancer.
    JAMA, 294(2): 238-44. [Abstract] [Full-text]
35. The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.
    Proc Natl Acad Sci U S A, 102(28): 9890-5. [Abstract] [Full-text]
36. Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression.
    J Pathol, 206(4): 423-32. [Abstract] [Full-text]
37. Incidentally detected prostate cancer in cystoprostatectomies: pathological and morphometric comparison with clinically detected cancer in totally embedded specimens.
    Hum Pathol, 36(6): 646-54. [Abstract] [Full-text]
38. Local anesthesia in transrectal ultrasound-guided prostate biopsy: EMLA cream as a new alternative technique.
    Scand J Urol Nephrol, 39(2): 130-4. [Abstract] [Full-text]
39. The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival.
    Scand J Urol Nephrol, 39(2): 117-23. [Abstract] [Full-text]
40. Coagulopathy, following medical therapy, for carcinoma of the prostate.
    Hematology, 10(1): 65-8. [Abstract] [Full-text]
41. Differences in glycosylation patterns of heat shock protein, gp96: implications for prostate cancer prevention.
    Cancer Res, 65(14): 6466-75. [Abstract] [Full-text]
42. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Cancer Res, 65(14): 6435-42. [Abstract] [Full-text]
43. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
    Cancer Res, 65(14): 6364-70. [Abstract] [Full-text]
44. Activation of nuclear factor-kappaB contributes to induction of death receptors and apoptosis by the synthetic retinoid CD437 in DU145 human prostate cancer cells.
    Cancer Res, 65(14): 6354-63. [Abstract] [Full-text]
45. A new three-dimensional ultrasound microimaging technology for preclinical studies using a transgenic prostate cancer mouse model.
    Cancer Res, 65(14): 6337-45. [Abstract] [Full-text]
46. CaSm-mediated cellular transformation is associated with altered gene expression and messenger RNA stability.
    Cancer Res, 65(14): 6228-36. [Abstract] [Full-text]
47. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products.
    Cancer Res, 65(14): 6189-98. [Abstract] [Full-text]
48. Quality assurance issues in radical prostatectomy.
    Eur J Surg Oncol, 31(6): 650-5. [Abstract] [Full-text]
49. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity.
    Cancer Gene Ther, 12(8): 715-22. [Abstract] [Full-text]
50. Dietary patterns and risk of prostate cancer in Ontario, Canada.
    Int J Cancer, 116(4): 592-8. [Abstract] [Full-text]
51. Association of plasminogen with dipeptidyl peptidase IV and Na+/H+ exchanger isoform NHE3 regulates invasion of human 1-LN prostate tumor cells.
    J Biol Chem, 280(29): 27173-8. [Abstract] [Full-text]
52. Absolute and relative dose-surface and dose-volume histograms of the bladder: which one is the most representative for the actual treatment?
    Phys Med Biol, 50(15): 3589-97. [Abstract] [Full-text]
53. A particle swarm optimization algorithm for beam angle selection in intensity-modulated radiotherapy planning.
    Phys Med Biol, 50(15): 3491-514. [Abstract] [Full-text]
54. Prostate cancer multi-feature analysis using trans-rectal ultrasound images.
    Phys Med Biol, 50(15): N175-85. [Abstract] [Full-text]
55. Genetic variants of DNA repair genes and prostate cancer: a population-based study.
    Cancer Epidemiol Biomarkers Prev, 14(7): 1703-9. [Abstract] [Full-text]
56. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer.
    Cancer Epidemiol Biomarkers Prev, 14(7): 1697-702. [Abstract] [Full-text]
57. Comparison of prostate-specific antigen and hormone levels among men in Singapore and the United States.
    Cancer Epidemiol Biomarkers Prev, 14(7): 1692-6. [Abstract] [Full-text]
58. Initial experience with megavoltage (MV) CT guidance for daily prostate alignments.
    Int J Radiat Oncol Biol Phys, 62(5): 1517-24. [Abstract] [Full-text]
59. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Int J Radiat Oncol Biol Phys, 62(5): 1322-31. [Abstract] [Full-text]
60. Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy.
    Int J Radiat Oncol Biol Phys, 62(5): 1316-21. [Abstract] [Full-text]
61. Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation.
    Int J Radiat Oncol Biol Phys, 62(5): 1309-15. [Abstract] [Full-text]
62. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
    Int J Radiat Oncol Biol Phys, 62(5): 1297-308. [Abstract] [Full-text]
63. Intraprostatic fiducials for localization of the prostate gland: monitoring intermarker distances during radiation therapy to test for marker stability.
    Int J Radiat Oncol Biol Phys, 62(5): 1291-6. [Abstract] [Full-text]
64. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
    Br J Cancer, 93(2): 173-7. [Abstract] [Full-text]
65. Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer.
    Jpn J Clin Oncol, 35(7): 365-74. [Abstract] [Full-text]
66. Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens.
    Mod Pathol, 18(8): 1022-6. [Abstract] [Full-text]
67. Tectorigenin and other phytochemicals extracted from leopard lily Belamcanda chinensis affect new and established targets for therapies in prostate cancer.
    Carcinogenesis, 26(8): 1360-7. [Abstract] [Full-text]
68. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
    J Clin Oncol, 23(21): 4591-601. [Abstract] [Full-text]
69. Malignant phyllodes tumor of the prostate.
    Arch Androl, 51(4): 295-8. [Abstract] [Full-text]
70. Epigallocatechin gallate inhibits HIF-1alpha degradation in prostate cancer cells.
    Biochem Biophys Res Commun, 334(2): 543-8. [Abstract] [Full-text]
71. Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer.
    Oncogene, 24(31): 4934-45. [Abstract] [Full-text]
72. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience.
    Radiology, 236(2): 545-53. [Abstract] [Full-text]
73. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice.
    Clin Chem, 51(8): 1342-51. [Abstract] [Full-text]
74. The role of anxiety in prostate carcinoma: a structured review of the literature.
    Cancer, 104(3): 467-78. [Abstract] [Full-text]
75. Prostate cancer and the genomic revolution: Advances using microarray analyses.
    Mutat Res, 576(1): 66-79. [Abstract] [Full-text]
76. The use of genetically engineered mouse models of prostate cancer for nutrition and cancer chemoprevention research.
    Mutat Res, 576(1): 111-9. [Abstract] [Full-text]
77. Inguinal hernia repair with polypropylene mesh during radical retropubic prostatectomy: an easy and practical approach.
    BJU Int, 96(3): 330-3. [Abstract] [Full-text]
78. Serum thyroid-stimulating hormone is elevated in men with Gleason 8 prostate cancer.
    BJU Int, 96(3): 328-9. [Abstract] [Full-text]
79. Increasing the number of biopsy cores improves the concordance of biopsy Gleason score to prostatectomy Gleason score.
    BJU Int, 96(3): 324-7. [Abstract] [Full-text]
80. Do all patients with high-grade prostatic intraepithelial neoplasia on initial prostatic biopsy eventually progress to clinical prostate cancer?
    BJU Int, 96(3): 320-3. [Abstract] [Full-text]
81. New perioperative management reduces bleeding in radical retropubic prostatectomy.
    BJU Int, 96(3): 316-9. [Abstract] [Full-text]
82. Analysis of peripheral blood for prostate cells after autologous transfusion given during radical prostatectomy.
    BJU Int, 96(3): 313-5. [Abstract] [Full-text]
83. Age-specific reference levels of serum prostate-specific antigen and prostate volume in healthy Arab men.
    BJU Int, 96(3): 308-12. [Abstract] [Full-text]
84. Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of <10 ng/mL.
    BJU Int, 96(3): 303-7. [Abstract] [Full-text]
85. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.
    JAMA, 294(4): 440-7. [Abstract] [Full-text]
86. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.
    JAMA, 294(4): 433-9. [Abstract] [Full-text]
87. The influence of occupational exposure to pesticides, polycyclic aromatic hydrocarbons, diesel exhaust, metal dust, metal fumes, and mineral oil on prostate cancer: a prospective cohort study.
    Occup Environ Med, 62(8): 531-7. [Abstract] [Full-text]
88. Usefulness of epithelial membrane antigen (EMA) to discriminate between perineural invasion and perineural indentation in prostatic carcinoma.
    Histopathology, 47(2): 159-65. [Abstract] [Full-text]
89. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
    Cancer Chemother Pharmacol, 56(4): 415-20. [Abstract] [Full-text]
90. Comparison of high-resolution echo-planar spectroscopic imaging with conventional MR imaging of prostate tumors in mice.
    NMR Biomed, 18(5): 285-92. [Abstract] [Full-text]
91. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure.
    J Clin Oncol, 23(22): 4975-9. [Abstract] [Full-text]
92. Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer.
    Mitochondrion, 5(3): 143-53. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.